RBC Capital raises Axsome Therapeutics price target to $304

0 min read Updated on 08 Jul 2026, 01:23 AM

Reviewed by

Radhika SScanX News Team

AI Summary

RBC Capital analyst Leonid Timashev maintained an Outperform rating on Axsome Therapeutics and raised the price target to $304 from $302.

*this image is generated using AI for illustrative purposes only.

RBC Capital analyst Leonid Timashev has maintained an Outperform rating on Axsome Therapeutics (NASDAQ: AXSM) and raised the price target to $304 from $302.

The adjustment reflects the firm's updated valuation outlook on the stock. The new price target represents a slight increase from the previous level of $302.

What specific factors are driving RBC's updated valuation outlook for Axsome Therapeutics?

How might Axsome's upcoming clinical trial results impact the stock's performance relative to the new price target?

What competitive landscape changes could influence Axsome's ability to meet the raised price target?

Read Next Article

Axsome doses first patient in FOCUS-2 Phase 3 ADHD trial

1 min read Updated on 07 Jul 2026, 05:25 PM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

AI Summary

Axsome Therapeutics advances its pediatric ADHD program by dosing the first patient in the FOCUS-2 Phase 3 trial for children aged 6 to 12. The study will evaluate solriamfetol's efficacy and safety in 468 patients over six weeks, with the primary endpoint measuring changes in ADHD-RS-5 scores. This follows the earlier launch of the FOCUS-3 trial for adolescents.

*this image is generated using AI for illustrative purposes only.

Axsome Therapeutics has dosed the first patient in its FOCUS-2 Phase 3 trial evaluating solriamfetol for children aged 6 to less than 12 years with Attention Deficit Hyperactivity Disorder (ADHD). The trial aims to assess the efficacy and safety of the treatment in this pediatric population, addressing a significant unmet medical need.

FOCUS-2 is a randomized, double-blind, placebo-controlled, multicenter study designed to evaluate two doses of solriamfetol against a placebo. Approximately 468 patients will be randomized in a 1:1:1 ratio to receive one of the two doses or the placebo for a treatment duration of six weeks.

The primary endpoint of the trial is the change from baseline to week 6 in the ADHD Rating Scale (ADHD-RS-5) total score. This measure will help determine the drug's impact on ADHD symptoms in children.

Previously, Axsome announced the initiation of the FOCUS-3 Phase 3 trial of solriamfetol in adolescents aged 12 to less than 18 years with ADHD. The progression of the pediatric clinical program underscores Axsome's commitment to developing treatments across different age groups affected by ADHD.

The trial design and endpoints are structured to provide robust data on the potential benefits and risks of solriamfetol in younger patients. Results from this study will inform future regulatory submissions and potential treatment options for children with ADHD.

What are the anticipated timelines for the release of top-line data from the FOCUS-2 trial?

How might the results from the FOCUS-3 adolescent trial influence the regulatory strategy for the FOCUS-2 pediatric indication?

What potential market impact could solriamfetol have on current ADHD treatment options for children if approved?